Hong Xie

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda, Antoîne Italiano, Cinta Hierro et al. · Clinical Cancer Research · 2019 · 244 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Peter M. Voorhees, Robert Manges, Pieter Sonneveld et al. · British Journal of Haematology · 2013 · 143 citations

Pharmacy, Immunology, Pharmacotherapy +17

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Jesús F. San Miguel, Joan Bladé, Ofer Shpilberg et al. · Blood · 2014 · 141 citations · Full text

Medicine, Immunology, Oncology +16

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Robert Z. Orlowski, Liana Gercheva, Cathy Williams et al. · American Journal of Hematology · 2014 · 132 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Sally A. Hunsucker, Valeria Magarotto, Deborah J. Kuhn et al. · British Journal of Haematology · 2011 · 79 citations · Full text

Medicine, Oncology, Pharmacology +15